Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome

Simple item page
dc.contributor.authorVasquez, Dario H.
dc.contributor.authorAltamirano, Juan C.
dc.contributor.authorCasaus, Angel
dc.contributor.authorDel Valle, Rodrigo A.
dc.contributor.authorGonzalez, Roberto
dc.contributor.authorGonzalez-De la Rosa, Alejandro
dc.contributor.authorNavarro-Partida, Jose
dc.contributor.authorVasquez, Martin A.
dc.contributor.authorSantos, Arturo
dc.date.accessioned2025-01-23T21:22:58Z
dc.date.available2025-01-23T21:22:58Z
dc.date.issued2018
dc.description.abstractPurpose: To report surgical outcomes in a series of cases with symptomatic vitreomacular traction thatmet MIVI-TRUST (Microplasmin for intravitreous injection-traction release without surgical treatment) criteria for ocriplasmin use who underwent primary 25-gauge vitrectomy.
dc.description.abstractMaterials and Methods: A single-center retrospective chart review study was performed in patients who underwent primary 25-gauge vitrectomy for symptomatic vitreomacular traction (VTM) from January 2013 through January 2016. Pre- and postoperative visual acuity (measured by the early treatment diabetic retinopathy acuity test), and posterior hyaloid focal attachment to the macula (demonstrated by high-definition optical coherence tomography) were analyzed. In addition, intra-and postoperative complications were obtained from medical records.
dc.description.abstractResults: Fifteen consecutive cases of symptomatic VMT traction that underwent primary 25-gauge vitrectomy were included. All met the MIVI-TRUST criteria for ocriplasmin use. In all cases, VMT resolution, macular hole closure, and improvement in best corrected visual acuity (BCVA) were observed. Mean visual acuity improved from 56.53 +/- 16.04 letters at baseline to 73.13 +/- 7.46 letters at 24 weeks of follow-up. The mean BCVA improvement from baseline was 16.60 letters (range 6-44), which was statistically significant (P < 0.0001). Ten of fifteen patients (66.6%) showed significant improvement of their BCVA to 20/40 or better (70 or more in ETDRS visual acuity test). No significant intra-or postoperative complications were documented.
dc.description.abstractConclusions: Primary 25-gauge pars plana vitrectomy in eyes with symptomatic vitreomacular traction is able to efficiently resolve VMT and macular holes, improving vision in candidates for intravitreal injection of ocriplasmin. This well-tolerated surgical procedure may be a reliable and predictable alternative for resolving VMT pathology.
dc.description.funderCentro de Retina Medica y Quirurgica, Jalisco, Mexico
dc.fuente.origenWOS
dc.identifier.doi10.1080/02713683.2017.1385086
dc.identifier.eissn1460-2202
dc.identifier.issn0271-3683
dc.identifier.urihttps://doi.org/10.1080/02713683.2017.1385086
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101269
dc.identifier.wosidWOS:000427324400009
dc.issue.numero2
dc.language.isoen
dc.pagina.final212
dc.pagina.inicio208
dc.revistaCurrent eye research
dc.rightsacceso restringido
dc.subjectRetina
dc.subjectvitreomacular traction
dc.subjectocriplasmin
dc.subjectmetamorphopsia
dc.subjectmacular hole
dc.titleSurgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome
dc.typeartículo
dc.volumen43
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas